Vav1 GEF activity is required for T cell mediated allograft rejection

Transplant Immunology

Volumn 26, Issue 4, 2012, Pages 212-219

  Haubert, Dirk ^a   Li, Jianping ^a   Saveliev, Alexander ^b   Calzascia, Thomas ^a   Sutter, Esther ^a   Metzler, Barbara ^a   Kaiser, Daniel ^a   Tybulewicz, Victor L J ^b   Weckbecker, Gisbert ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Allograft rejection; RhoGTPase; T cells; Vav

Indexed keywords

ALLOANTIBODY; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PROTEIN VAV1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; DNA-BINDING PROTEINS; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEART TRANSPLANTATION; IMMUNOSUPPRESSION; ISOANTIGENS; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; MUTATION; PROTO-ONCOGENE PROTEINS C-VAV; T-LYMPHOCYTES; TRANSCRIPTION FACTORS;

EID: 84860494600     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2012.03.003     Document Type: Article

References (37)

1. Nankivell B.J., Alexander S.I. Rejection of the kidney allograft. N Engl J Med Oct 7 2010, 363(15):1451-1462.
2. Halloran P.F. Immunosuppressive drugs for kidney transplantation. N Engl J Med Dec 23 2004, 351(26):2715-2729.
3. Lechler R.I., Sykes M., Thomson A.W., Turka L.A. Organ transplantation-how much of the promise has been realized?. Nat Med Jun 2005, 11(6):605-613.
4. Scherer M.N., Banas B., Mantouvalou K., Schnitzbauer A., Obed A., Kramer B.K., et al. Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg Sep 2007, 392(5):511-523.
5. Valujskikh A., Baldwin W.M., Fairchild R.L. Recent progress and new perspectives in studying T cell responses to allografts. Am J Transplant May 2010, 10(5):1117-1125.
6. Turner M., Billadeau D.D. VAV proteins as signal integrators for multi-subunit immune-recognition receptors. Nat Rev Immunol Jul 2002, 2(7):476-486.
7. Tybulewicz V.L. Vav-family proteins in T-cell signalling. Curr Opin Immunol Jun 2005, 17(3):267-274.
8. Turner M., Mee P.J., Walters A.E., Quinn M.E., Mellor A.L., Zamoyska R., et al. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity Oct 1997, 7(4):451-460.
9. Costello P.S., Walters A.E., Mee P.J., Turner M., Reynolds L.F., Prisco A., et al. The Rho-family GTP exchange factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and NF-kappaB pathways. Proc Natl Acad Sci U S A Mar 16 1999, 96(6):3035-3040.
10. Reynolds L.F., de B.C., Norton T., Beeser A., Chernoff J., Tybulewicz V.L. Vav1 transduces T cell receptor signals to the activation of the Ras/ERK pathway via LAT, Sos, and RasGRP1. J Biol Chem Apr 30 2004, 279(18):18239-18246.
11. Reynolds L.F., Smyth L.A., Norton T., Freshney N., Downward J., Kioussis D., et al. Vav1 transduces T cell receptor signals to the activation of phospholipase C-gamma1 via phosphoinositide 3-kinase-dependent and -independent pathways. J Exp Med May 6 2002, 195(9):1103-1114.
12. Ardouin L., Bracke M., Mathiot A., Pagakis S.N., Norton T., Hogg N., et al. Vav1 transduces TCR signals required for LFA-1 function and cell polarization at the immunological synapse. Eur J Immunol Mar 2003, 33(3):790-797.
13. Krawczyk C., Oliveira-dos-Santos A., Sasaki T., Griffiths E., Ohashi P.S., Snapper S., et al. Vav1 controls integrin clustering and MHC/peptide-specific cell adhesion to antigen-presenting cells. Immunity Mar 2002, 16(3):331-343.
14. Chrencik J.E., Brooun A., Zhang H., Mathews I.I., Hura G.L., Foster S.A., et al. Structural basis of guanine nucleotide exchange mediated by the T-cell essential Vav1. J Mol Biol Jul 25 2008, 380(5):828-843.
15. Rapley J., Tybulewicz V.L., Rittinger K. Crucial structural role for the PH and C1 domains of the Vav1 exchange factor. EMBO Rep Jul 2008, 9(7):655-661.
16. Li P., Martins I.R., Amarasinghe G.K., Rosen M.K. Internal dynamics control activation and activity of the autoinhibited Vav DH domain. Nat Struct Mol Biol Jun 2008, 15(6):613-618.
17. Aghazadeh B., Lowry W.E., Huang X.Y., Rosen M.K. Structural basis for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation. Cell Sep 1 2000, 102(5):625-633.
18. Dumont C., Corsoni-Tadrzak A., Ruf S., de B.J., Williams A., Turner M., et al. Rac GTPases play critical roles in early T-cell development. Blood Apr 23 2009, 113(17):3990-3998.
19. Gomez M., Tybulewicz V., Cantrell D.A. Control of pre-T cell proliferation and differentiation by the GTPase Rac-I. Nat Immunol Oct 2000, 1(4):348-352.
20. Saveliev A., Vanes L., Ksionda O., Rapley J., Smerdon S.J., Rittinger K., et al. Function of the nucleotide exchange activity of vav1 in T cell development and activation. Sci Signal 2009, 2(101):ra83.
21. Paccani S.R., Boncristiano M., Patrussi L., Ulivieri C., Wack A., Valensin S., et al. Defective Vav expression and impaired F-actin reorganization in a subset of patients with common variable immunodeficiency characterized by T-cell defects. Blood Jul 15 2005, 106(2):626-634.
22. Korn T., Fischer K.D., Girkontaite I., Kollner G., Toyka K., Jung S. Vav1-deficient mice are resistant to MOG-induced experimental autoimmune encephalomyelitis due to impaired antigen priming. J Neuroimmunol Jun 2003, 139(1-2):17-26.
23. Weckbecker G., Bruns C., Fischer K.D., Heusser C., Li J., Metzler B., et al. Strongly reduced alloreactivity and long-term survival times of cardiac allografts in Vav1- and Vav1/Vav2-knockout mice. Transpl Int Apr 2007, 20(4):353-364.
24. Corry R.J., Winn H.J., Russell P.S. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation Oct 1973, 16(4):343-350.
25. Stewart S., Winters G.L., Fishbein M.C., Tazelaar H.D., Kobashigawa J., Abrams J., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant Nov 2005, 24(11):1710-1720.
26. Fujikawa K., Miletic A.V., Alt F.W., Faccio R., Brown T., Hoog J., et al. Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cells. J Exp Med Nov 17 2003, 198(10):1595-1608.
27. Charvet C., Canonigo A.J., Becart S., Maurer U., Miletic A.V., Swat W., et al. Vav1 promotes T cell cycle progression by linking TCR/CD28 costimulation to FOXO1 and p27kip1 expression. J Immunol Oct 15 2006, 177(8):5024-5031.
28. Kountouras J., Zavos C., Chatzopoulos D. Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease. J Cell Mol Med Jul 2004, 8(3):317-328.
29. Wang S., Diao H., Guan Q., Jevnikar A.M., Du C. Enhanced cardiac allograft survival by Vav1-Rac signaling blockade in a mouse model. Transpl Immunol Jul 2007, 18(1):53-61.
30. Gulbranson-Judge A., Tybulewicz V.L., Walters A.E., Toellner K.M., MacLennan I.C., Turner M. Defective immunoglobulin class switching in Vav-deficient mice is attributable to compromised T cell help. Eur J Immunol Feb 1999, 29(2):477-487.
31. Bachmann M.F., Nitschke L., Krawczyk C., Tedford K., Ohashi P.S., Fischer K.D., et al. The guanine-nucleotide exchange factor Vav is a crucial regulator of B cell receptor activation and B cell responses to nonrepetitive antigens. J Immunol Jul 1 1999, 163(1):137-142.
32. Vicente-Manzanares M., Cruz-Adalia A., Martin-Cofreces N.B., Cabrero J.R., Dosil M., Alvarado-Sanchez B., et al. Control of lymphocyte shape and the chemotactic response by the GTP exchange factor Vav. Blood Apr 15 2005, 105(8):3026-3034.
33. David R., Ma L., Ivetic A., Takesono A., Ridley A.J., Chai J.G., et al. T-cell receptor- and CD28-induced Vav1 activity is required for the accumulation of primed T cells into antigenic tissue. Blood Apr 16 2009, 113(16):3696-3705.
34. Michel F., Mangino G., Attal-Bonnefoy G., Tuosto L., Alcover A., Roumier A., et al. CD28 utilizes Vav-1 to enhance TCR-proximal signaling and NF-AT activation. J Immunol Oct 1 2000, 165(7):3820-3829.
35. Dennehy K.M., Elias F., Na S.Y., Fischer K.D., Hunig T., Luhder F. Mitogenic CD28 signals require the exchange factor Vav1 to enhance TCR signaling at the SLP-76-Vav-Itk signalosome. J Immunol Feb 1 2007, 178(3):1363-1371.
36. Rudd C.E., Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol Jul 2003, 3(7):544-556.
37. Marinari B., Costanzo A., Viola A., Michel F., Mangino G., Acuto O., et al. Vav cooperates with CD28 to induce NF-kappaB activation via a pathway involving Rac-1 and mitogen-activated kinase kinase 1. Eur J Immunol Feb 2002, 32(2):447-456.